Arrowhead Pharmaceuticals (ARWR) Competitors $13.47 -0.05 (-0.37%) Closing price 04:00 PM EasternExtended Trading$13.48 +0.01 (+0.07%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARWR vs. BBIO, LEGN, TGTX, TLX, BPMC, SRPT, NUVL, AXSM, VRNA, and GRFSShould you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Verona Pharma (VRNA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Arrowhead Pharmaceuticals vs. BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Nuvalent Axsome Therapeutics Verona Pharma Grifols BridgeBio Pharma (NASDAQ:BBIO) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking. Which has preferable valuation and earnings, BBIO or ARWR? BridgeBio Pharma has higher revenue and earnings than Arrowhead Pharmaceuticals. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M31.16-$535.76M-$2.85-12.78Arrowhead Pharmaceuticals$2.50M739.86-$599.49M-$5.17-2.61 Does the media refer more to BBIO or ARWR? In the previous week, BridgeBio Pharma had 10 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 20 mentions for BridgeBio Pharma and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.45 beat BridgeBio Pharma's score of 0.69 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer BBIO or ARWR? Arrowhead Pharmaceuticals received 373 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 72.13% of users gave BridgeBio Pharma an outperform vote while only 65.51% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes17672.13% Underperform Votes6827.87% Arrowhead PharmaceuticalsOutperform Votes54965.51% Underperform Votes28934.49% Which has more risk & volatility, BBIO or ARWR? BridgeBio Pharma has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Do analysts prefer BBIO or ARWR? BridgeBio Pharma currently has a consensus price target of $53.00, indicating a potential upside of 45.52%. Arrowhead Pharmaceuticals has a consensus price target of $41.44, indicating a potential upside of 207.68%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals & insiders believe in BBIO or ARWR? 99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is BBIO or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-241.44% N/A -75.69% Arrowhead Pharmaceuticals N/A -236.60%-64.09% SummaryBridgeBio Pharma beats Arrowhead Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARWR vs. The Competition Export to ExcelMetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$6.81B$5.52B$7.84BDividend YieldN/A3.11%5.11%4.23%P/E Ratio-2.617.3322.4018.52Price / Sales739.86240.73399.75103.35Price / CashN/A65.8538.1834.62Price / Book8.756.396.744.24Net Income-$599.49M$142.94M$3.22B$248.05M7 Day Performance8.98%4.55%4.35%5.04%1 Month Performance-2.53%-1.53%-0.80%1.70%1 Year Performance-41.76%-2.42%16.67%4.20% Arrowhead Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARWRArrowhead Pharmaceuticals3.6088 of 5 stars$13.47-0.4%$41.44+207.7%-38.9%$1.85B$2.50M-2.61400News CoveragePositive NewsBBIOBridgeBio Pharma4.5408 of 5 stars$33.32-1.6%$53.00+59.1%+44.3%$6.34B$221.90M-11.69400Earnings ReportOptions VolumeNews CoverageLEGNLegend Biotech2.628 of 5 stars$32.11-2.1%$79.00+146.0%-23.4%$5.90B$627.24M-33.801,070TGTXTG Therapeutics3.3463 of 5 stars$36.85-3.8%$40.67+10.4%+212.0%$5.79B$329.00M-368.46290News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.32-2.3%$22.00+34.8%N/A$5.51B$783.21M0.00N/AAnalyst RevisionNews CoverageBPMCBlueprint Medicines2.5877 of 5 stars$84.30-0.5%$124.95+48.2%-4.8%$5.39B$508.82M-78.05640Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsSRPTSarepta Therapeutics4.6769 of 5 stars$55.13+2.5%$158.70+187.9%-52.2%$5.35B$1.90B44.10840Upcoming EarningsNUVLNuvalent1.9177 of 5 stars$70.12-2.1%$115.50+64.7%+12.5%$5.02BN/A-20.2140News CoveragePositive NewsAXSMAxsome Therapeutics4.8282 of 5 stars$102.36-2.0%$169.80+65.9%+49.5%$4.99B$385.69M-17.09380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsVRNAVerona Pharma2.0918 of 5 stars$60.20+2.2%$75.43+25.3%+344.9%$4.87B$42.28M-31.3530Analyst ForecastShort Interest ↓News CoveragePositive NewsGap UpGRFSGrifols3.8843 of 5 stars$6.97-1.6%N/A+12.1%$4.79B$7.21B5.9626,300Short Interest ↓Positive News Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Sarepta Therapeutics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives Verona Pharma Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARWR) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts